Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Myocardial Infarction
and you are
between 18 and 80
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. This is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would enrolled a total of 380 AMI patients undergoing percutaneous coronary intervention (PCI) to one of two antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone. All enrolled patients would be followed-up to 30 days.

Provided treatments

  • Drug: Bivalirudin
  • Drug: heparin
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02897037. The sponsor of the trial is Shenzhen Salubris Pharmaceuticals Co., Ltd. and it is looking for 380 volunteers for the current phase.
Official trial title:
Bivalirudin vs Heparin During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: A Randomised Controlled Trial